The transdermal matrixˆlms of metoprolol tartrate (MT) were prepared by casting on mercury substrate employing diŠerent ratios of polymers, ethyl cellulose (EC) and polyvinyl pyrrolidone (PVP), using dibutyl phthalate (DBT) as a plasticizer. Four formulations were prepared. Formulations MF-1, MF-2, MF-3 and MF-4 were composed of EC and PVP in the following ratios: 4.5：0.5, 4：1, 3：2 and 2：3 respectively. The formulations were subjected to various physical characterization studies namely, thickness, weight variation, drug content, moisture uptake, in vitro drug release and in vitro skin permeation. The in vitro permeation studies were carried out across excised porcine ear skin using Franz diŠusion cell. Cumulative amounts of the drug released in 24 hours from the four formulations were 69.58％, 96.13％, 98.85％ and 99.60％, respectively. Corresponding values for the cumulated amounts of drug permeated across the porcine skin for the above matrixˆlms were 124. 38, 153.22, 156.46 and 163.25 mg/cm 2 respectively. Byˆtting the data into zero order,ˆrst order and Higuchi model, it was concluded that drug release from matrixˆlms followed Higuchi model (r 2 ＝0.9147 0.9823), and the mechanism of release was diŠusion mediated. Based on the physical evaluation, in vitro drug release & permeation characteristics, it was concluded that for potential therapeutic use, monolithic drug matrixˆlms MF-3, composed of EC: PVP (3：2), may be suitable for the development of a transdermal drug delivery system of MT.
INTRODUCTION
The formulations for skin are of two types depending on the target site of action of the incorporated drug(s). One exhibits systemic eŠects after the drug uptake from the cutaneous microvasculature network and the other shows local eŠects in the skin. The pharmacological eŠects of the former formulations are in‰uenced by the penetration of drug molecules through stratum corneum. 1 4) The development of technology for transdermal delivery of a drug at a predetermined rate into systemic circulation has become popular for various reasons such as avoidance ofˆrst pass eŠect, enhanced e‹cacy and improved patient compliance. The release of drugs through polymerˆlms is dependent on properties of the polymers and plasticizers. 5, 6) The study of in vitro drug permeation kinetics through a model skin is important in evaluation of a transdermal drug delivery system and it is also valuable for studying the rate and mechanism of percutaneous absorption of drugs.
Metoprolol tartrate is used as a b-adrenoreceptor blocker. It has a mean plasma half life of 4 hours. Only 40％ of the orally administered drug reaches the systemic circulation due to hepaticˆrst pass metabolism. The short plasma half life makes frequent dosing necessary to maintain the therapeutic blood levels of the drug for a long term treatment of hypertension. 7 10) The objective of the present study was to develop and evaluate diŠerent transdermal polymeric matrixˆlms of EC and PVP containing metoprolol tartrate to avoid the hepaticˆrst-pass eŠect and improve therapeutic e‹cacy of the drug. For in vitro permeation studies excised pig ear skin was used as a model. 11, 12) An attempt was made tô nd out a combination of polymers EC and PVP to formulate transdermal matrixˆlms with good physical characteristics as well as in vitro drug release and permeation properties. 
MATERIALS AND METHODS

Materials
Metoprolol tartrate (Astra Zeneca, India), Ethyl cellulose (S. D.ˆne chemicals, Mumbai), Polyvinyl pyrrolidone K-30 (Himedia Labs, Mumbai), Dibutyl phthalate (Qualigenˆne chemicals, Mumbai) were used. All reagents and solvents were of analytically graded and used as received.
Compatibility Studies
The compatibility studies were carried in order toˆnd out possible interaction between MT and the formulation ingredients. Brie‰y, 50 mg of drug along with the same amount of formulation additives were placed into separate stoppered volumetric ‰asks and the volume was made up to 50 ml with phosphate buŠered saline pH 7.4 (PBS). The solutions were kept at room temperature for 24 hours with intermittent shaking. At the end of the interaction period, the samples were taken and after suitable dilutions analyzed for drug content at 223 nm using a UV spectrophotometer (Perkin Elmer, model EZ 301). A change in the absorption peak or a shift in the wavelength of absorption was considered as an interaction.
Preparation of Monolithic Drug Loaded Films
Four polymeric matrixˆlms were prepared by casting on mercury surface. 13) Brie‰y, the polymer solution (10％ w/v) was prepared in chloroform by dissolving EC and PVP (ratios 4.5：0.5, 4：1, 3：2 and 2：3 corresponding to formulations MF-1, MF-2, MF-3 and MF-4 respectively) along with plasticizer DBP (15％ w/w of the polymer weight) and the drug MT (30％ w/w of polymer weight) ( Table 1 ). The ingredients were dissolved by stirring for 30 min using a magnetic stirrer bar. The homogenous polymer solution was poured into glass rings placed on the surface of mercury kept in a Petri dish. The solvent was allowed to evaporate at room temperature and evaporation was controlled by placing an inverted funnel over the Petri dish. A locally fabricated patch die was used to cut out matrixˆlms of desired size from the cast lm. Theˆlms were stored in desiccators until used for physical characterization and permeation studies.
Physical Evaluation of Matrix Films The monolithic matrixˆlms of the drug were evaluated for the following physical characteristics.
Thickness The thickness of a matrixˆlm was measured at four points using a thickness gauge employed for plasticˆlms (Proliˆc Engineers, NOIDA, India). For each formulation three randomly selectedˆl ms were used.
Weight variation
Sixˆlms from each formulation batch were cut out using a patch die of 1.5 cm diameter, weighed individually and the average weight was calculated toˆnd out the percent weight variation.
Drug content A matrixˆlm of the size speciˆed above was cut into small pieces using a sharp blade and transferred into USP dissolution apparatus vessel containing 900 ml of phosphate buŠered saline pH 7.4 and stirred with paddle (50 rpm) at 37±0.5°C for two hours to ensure complete dissolution/release of the drug into the buŠer. The solution was analyzed for drug content at 223 nm using UV spectrophotometer. The samples were taken until the absorbance readings became constant (about 3 hours). The drug content of the matrixˆlm was calculated with the help of a standard curve. All the experiments were carried out in triplicate.
Moisture uptake The matrixˆlm of the size speciˆed above was accurately weighed, wrapped in aluminium foil and placed in desiccators containing a saturated solution of aluminium chloride (79.05％ RH). After three day, theˆlm was taken out and weighed again. The percent moisture uptake was calculated from the diŠerence between the initial andˆnal weights. All the experiments were carried out in triplicate. The results of all the above matrixˆlm evaluations are shown in Table 2 .
Flatness The constriction of aˆlm strip cut out from a drug loaded matrixˆlm is an indicator of its ‰atness. Brie‰y, longitudinal strips (1.5×0.75 cm length) were cut out from the prepared medicated matrixˆlms. The initial length of each strip was measured, and then they were kept at room temperature for 30 min. The variation in the length due to the nonuniformity in ‰atness was measured. Flatness was calculated by measuring constriction of strips and a zero 
Data represent mean of three observations. percent constriction was considered to be equal to hundred percent ‰atness. The experiments were carried out in triplicate ( Table 3) .
where, L 1 is initial length and L 2 isˆnal length of the strip.
In Vitro Drug Release Studies A modiˆed paddle over disc USP dissolution apparatus was used in these studies. 14) A transdermal matrixˆlm was mounted on the disc and placed at the bottom of the dissolution vessel. The dissolution medium was 900 ml of phosphate buŠered saline of pH 7.4. The apparatus was equilibrated to 37±0.5°C and the stirrer paddle speed was set at 50 rpm. The samples were withdrawn at appropriate time intervals and analyzed at 223 nm using a spectrophotometer. The amount of drug released was calculated from the standard curve. All the experiments were carried out in triplicate.
In Vitro Skin Permeation Studies The transdermal permeation studies were carried out using a modied Franz diŠusion cell taking porcine skin as an in vitro model. 15) The porcine skin from pinna was procured from a local slaughter house. The skin samples were clipped, excised, cleaned with phosphate buŠered saline and mounted on the diŠusion cell with the stratum corneum side facing the donor compartment. 16) The receptor compartment wasˆlled with PBS at 37±0.5°C. The matrixˆlm was cut out, measured and placed on the skin. The donor compartment was covered with a sheet of aluminium foil and wrapped with a piece of stretchable plasticˆlm to prevent evaporation/drying. At predetermined time intervals, samples were withdrawn from the receptor compartment and the cell was reˆlled with an equal amount of fresh pre-warmed buŠer solution. After suitable dilutions the samples were analyzed at 223 nm by a spectrophotometer. All the experiments were carried out in triplicate.
Statistical Analysis
The results were expressed as arithmetic mean±S.D. The statistical analysis was performed using Student's paired t-test. The data was considered signiˆcant at p＜0.05.
RESULTS AND DISCUSSION
Matrix type transdermalˆlms containing metoprolol tartrate with diŠerent ratios of polymers, ethyl cellulose and polyvinyl pyrrolidone, were prepared and evaluated for various physical and permeation characteristics. The possible interaction between drug and the additives was studied by carefully designed compatibility studies. There was no interaction between the drug and polymers and plasticizers as evident from the absence of any diŠerence in the ultraviolet absorption values at 223 nm between the pure drug solution and the drug solutions containing additives. The results of the physical evaluation of matrix lms are shown in Table 2 . The thickness and weight of matrixˆlms were found to be uniform, which is indicated by low standard deviation values among diŠerent batches. This suggests an even distribution of the drug and the polymers in the matrixˆlm cast over the mercury surface. Good uniformity in the drug content among the batches was observed for all the formulations and the percent drug recovery ranged from 98.77±0.74％ for formulation MF-1 to 99.77±0.28％ for formulation MF-4 ( Table 2 ). The moisture uptake was found to increase slightly with increasing concentration of the hydrophilic polymer PVP in theˆlms. The moisture present in the matrix lms helps in maintaining suppleness thus preventing drying and brittleness. Furthermore, a low moisture uptake protects theˆlms from microbial contamination as well as bulkiness of the transdermal patches. Due to moisture uptake from the atmosphere, sig-niˆcant changes in properties like increased total porosity, pore diameter and reduced crushing strength has been reported for matrixˆlms containing hydrophilic polymers. 17) The ‰atness studies conducted on the matrixˆlms did not show any constriction as indicated by 100％ ‰atness for all the formulations ( Table 3 ). Therefore theˆlms are expected to maintain a smooth surface when applied onto skin. The drug content studies indicate that the drug was homogeneously dispersed in the matrixˆlms ( Table   2 ). The release of a drug from matrixˆlms is controlled by physico-chemical properties of the drug and the polymers used. In this study, the polymeriĉ lms of diŠerent combinations of EC and PVP released variable amounts of metoprolol tartrate. The cumulative amount of drug released in 24 hours was the highest at 99.60±0.52％ from formulation MF-4, containing EC and PVP in 2：3 ratios ( Table 4 and Fig. 1 ). Furthermore, the cumulative amount of drug permeated across porcine skin was also found to be the highest for the formulation MF-4, with a 24 hour ‰ux value being 163.25±4.21 mg/cm 2 ( Table 4 and Fig. 2) . However, the matrixˆlms MF-4 were found to be too soft and slightly unmanageable. Moreover, there was no signiˆcant diŠerence observed between the three formulations MF-2, MF-3 and MF-4 in terms of the amount of drug released as well as the amount permeated through skin in vitro. Therefore, based on better physical characteristics, we selected formulation MF 3 containing EC and PVP in 3：2 ratio as the optimized formulation for further studies. 18) The release of a drug from a transdermal drug delivery system occurs by diŠusion, which involves transport of a drug from the polymer matrix into the in vitro study medium depending on concentration. 19, 20) As the gradient varies, the drug is released and the distance for diŠusion becomes increasingly greater. This could be an explanation why the drug diŠuses comparatively at a slower rate as the distance for diŠusion increases. 21) Initially a rapid drug release and permeation were observed, which gradually approached plateau values ( Figs. 1 and 2) , thus conrming the controlled release behavior of the matrix formulations. The initial quick migration of the drug towards the matrix surface would help achieve the therapeutic plasma concentration of the drug and the relatively constant release later on would then provide a sustained and controlled release of the drug.
Release Mechanism Investigation
The dissolution studies were performed using the USP paddleover-disc method (50 rpm). The objective was to estimate, characterize and rationalize the drug release from matrixˆlms. The in vitro dissolution proˆles are often used as surrogates, indicating how a drug will behave in vivo. The quantitative analysis of the values obtained in dissolution tests is easier when mathematical equations that express the dissolution results as a function of some of the dosage form characteristics are used. Drug dissolution from solid dosage forms has been described by kinetic models such as zero order,ˆrst order, Higuchi, Peppas and Hixon-Crowell. 22) However, the Higuchi model remains one of the most popular mathematical models that have been employed for studying the drug release mechanisms from polymericˆlms. 23 25) This model is applicable when diŠusion is primary drug release controlling mechanism. Peppas 26) introduced the power law equation M t /M∞＝kt n to explain the drug release by coupling Fickian and non-Fickian mechanisms. The value of exponent n was used to characterize diŠerent release mechanisms. (n＝0.5, for Fickian diŠusion; 0.5 〈n〉 1.0 or n＝1.0 or higher, for non-Fickian diŠusion). The value of n can be calculated from the slope of ln M t /M∞ vs ln t. This model is generally used to analyze the drug release from polymeric dosage forms, when the release mechanism is not well known or when more than one type of release phenomena could be involved. 27) In order to propose a release mechanism, MT release data wasˆtted to zero-order,ˆrst-order and the Higuchi empiric mathematical model. The in vitro drug release proˆles did notˆt into the zero-order kinetics (r 2 ＝0.7112 0.8600) orˆrst-order kinetics (r 2 ＝0.2965 0.4448). However, the drug release was found to follow Higuchian kinetics, as the correlation coe‹cient (r 2 value) was the highest for this model (r 2 ＝0.9147 9823), indicating that the drug release was governed by a Fickian diŠusion mechanism. Water soluble drugs are released from the polymer matrix primarily by diŠusion, while poorly watersoluble drugs are released predominantly by erosion mechanism. 28, 29) The equations for the mathematical models employed in our study along with the results are shown in Table 5 . The results suggest that PVP, being a hydrophilic polymer, has a major in‰uence on drug release, permeation and physical characteristics of theˆlms, as evidenced by an increase in the amount of drug release and permeation, with increase in the proportion of PVP in formulations MF-1 to MF-4. Thus, based on physical attributes of matrix lms and satisfactory release and permeation proˆles, formulation MF-3 (EC：PVP, 3：2) was selected for development of a transdermal drug delivery system for metoprolol tartrate.
Current models for transdermal delivery assume that the drug diŠusivity in the membrane remains constant during transport i.e., the membrane is un- Where f t is the fraction of drug released in time t; k 0 , k 1 and k H are the rate constants for zero-order,ˆrst-order and Higuchian release, respectively; r 2 is the coe‹cient of correlation for each model. aŠected by the formulation. However, the aim of a transdermal formulation is to maximize delivery, either by occluding the skin or by releasing the vehicle components that enhance drug penetration. Thus, the membrane is being changed by the formulation. Therefore, a possible advance will be the development of mathematical models that incorporate time-dependent diŠusivity that re‰ect the eŠect of formulation on the membrane barrier, without compromising the assumption that the membrane remains basically un-modiˆed during the passing of the permeant, diŠusion coe‹cient remaining constant. 30) 
CONCLUSION
On the basis of the in vitro evaluations of the matrixˆlm formulations, it can be reasonably concluded that metoprolol tartrate can be formulated into transdermal polymeric matrixˆlms for development of a transdermal drug delivery system. The formulation MF-3 (EC：PVP, 3：2) was found to be the best one and it may be employed for further pharmacokinetic and pharmacodynamic studies in suitable animal models and human beings.
